Gil BVBA - Erytech Pharma CEO Director
| ERYPDelisted Stock | USD 0.78 0.04 4.88% |
Insider
Gil BVBA is CEO Director of Erytech Pharma SA
| Age | 61 |
| Phone | 33 4 78 74 44 38 |
| Web | https://www.erytech.com |
Erytech Pharma Management Efficiency
The company has return on total asset (ROA) of (0.3014) % which means that it has lost $0.3014 on every $100 spent on assets. This is way below average. Erytech Pharma's management efficiency ratios could be used to measure how well Erytech Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Erytech Pharma SA currently holds 13.57 M in liabilities with Debt to Equity (D/E) ratio of 1.0, which is about average as compared to similar companies. Erytech Pharma SA has a current ratio of 2.21, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Erytech Pharma's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| CGMA CPA | Soligenix | 52 | |
| Chung Huen | Aptorum Group Ltd | 44 | |
| Sarah Longoria | Exicure | 42 | |
| Erin Butler | Armata Pharmaceuticals | N/A | |
| Duane BA | Armata Pharmaceuticals | 74 | |
| Pascal Prigent | Genfit | 55 | |
| Evan Hecker | Ikena Oncology | N/A | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Roger MD | Addex Therapeutics | 67 | |
| Nick Rigopoulos | XORTX Therapeutics | N/A | |
| Timothy Dyer | Addex Therapeutics | 56 | |
| MRCP MD | XORTX Therapeutics | 74 | |
| Clark Cheng | Aptorum Group Ltd | 44 | |
| Xiaoqin MD | Avenue Therapeutics | 49 | |
| Gerald Goodman | Nutriband | 76 | |
| Robert Lutjens | Addex Therapeutics | 56 | |
| Peter Rhode | HCW Biologics | 66 | |
| Alexandra MD | Avenue Therapeutics | 57 | |
| WenChen MD | Surrozen | 60 | |
| Hing Wong | HCW Biologics | 70 | |
| MPA MD | Unicycive Therapeutics | 51 | |
Management Performance
| Return On Equity | -0.0098 | |||
| Return On Asset | -0.3 |
Erytech Pharma SA Leadership Team
Elected by the shareholders, the Erytech Pharma's board of directors comprises two types of representatives: Erytech Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Erytech. The board's role is to monitor Erytech Pharma's management team and ensure that shareholders' interests are well served. Erytech Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Erytech Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gil BVBA, CEO Director | ||
| Iman MD, Chief Officer | ||
| Philip Lorenzi, Consultant Board | ||
| AnneCcile Fumey, HR Director | ||
| Brian Schwab, Chief Counsel | ||
| Naomi Eichenbaum, Director Relations | ||
| Eric Soyer, CFO, COO | ||
| Bridget Bax, Consultant Board | ||
| Jrme PharmD, Chief Operations | ||
| Pr MD, Consultant Board |
Erytech Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Erytech Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0098 | |||
| Return On Asset | -0.3 | |||
| Profit Margin | (0.03) % | |||
| Operating Margin | (4.08) % | |||
| Current Valuation | 211.16 K | |||
| Shares Outstanding | 34.12 M | |||
| Shares Owned By Institutions | 7.65 % | |||
| Number Of Shares Shorted | 17.79 K | |||
| Price To Earning | (5.88) X | |||
| Price To Book | 0.65 X |
Pair Trading with Erytech Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Erytech Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Erytech Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Erytech Stock
| 0.38 | BAC | Bank of America Aggressive Push | PairCorr |
| 0.34 | TRV | The Travelers Companies Fiscal Year End 17th of January 2025 | PairCorr |
The ability to find closely correlated positions to Erytech Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Erytech Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Erytech Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Erytech Pharma SA to buy it.
The correlation of Erytech Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Erytech Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Erytech Pharma SA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Erytech Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in Erytech Stock
If you are still planning to invest in Erytech Pharma SA check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Erytech Pharma's history and understand the potential risks before investing.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |